SCHEMBL10257585

SCHEMBL10257585

CS(=O)(=O)NC(=O)c1c(-c2ccc[nH]c2=O)c2cc(OC(F)(F)F)ccc2n1Cc1cc(F)ccc1F

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.40
CYP2C8 P10632 1/20 0.39
F2RL3 Q96RI0 7/20 0.38
SCN9A Q15858 2/20 0.37
SCN5A Q14524 2/20 0.37
ABL1 P00519 1/20 0.37
SERPINE1 P05121 1/20 0.36
CYP2C9 P11712 3/20 0.34
CYP1A2 P05177 2/20 0.34
CYP3A4 P08684 2/20 0.34
CYP2D6 P10635 2/20 0.34
SCN7A Q01118 1/20 0.34
PTGDR2 Q9Y5Y4 2/20 0.33
SCN8A Q9UQD0 1/20 0.33
SCN10A Q9Y5Y9 1/20 0.33
DDR1 Q08345 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL862333 0.94 F2RL3 (0.45) PPARGCYP2C8F2RL3SCN9ASCN5A
SCHEMBL862215 0.92 PPARG (0.43) PPARGCYP2C8F2RL3SCN9ASCN5A
SCHEMBL862217 0.92 PPARG (0.43) PPARGCYP2C8SCN9ACYP2C9CYP1A2
SCHEMBL830885 0.91 EDNRB (0.40) PPARGCYP2C8SCN9ASCN5APTGDR2
SCHEMBL832029 0.89 PPARG (0.43) PPARGCYP2C8SCN9ASCN5APTGDR2
SCHEMBL862341 0.89 PPARG (0.40) PPARGCYP2C8F2RL3ABL1SERPINE1
SCHEMBL862206 0.89 CYP2C8 (0.43) PPARGCYP2C8F2RL3SCN9ASCN5A
SCHEMBL862182 0.88 CYP2C8 (0.40) PPARGCYP2C8SCN9APTGDR2
SCHEMBL831268 0.88 CYP2C8 (0.45) PPARGCYP2C8SCN9ACYP1A2PTGDR2
SCHEMBL831198 0.88 CYP2C8 (0.43) PPARGCYP2C8SCN9ASCN5APTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 PPARG 4093/4885CYP2C8 847/4885F2RL3 1782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.